HK1094530A1 - N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt - Google Patents
N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid saltInfo
- Publication number
- HK1094530A1 HK1094530A1 HK07101468.4A HK07101468A HK1094530A1 HK 1094530 A1 HK1094530 A1 HK 1094530A1 HK 07101468 A HK07101468 A HK 07101468A HK 1094530 A1 HK1094530 A1 HK 1094530A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- benzamidine
- pentoxy
- thiazol
- phenoxy
- isopropyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/28—Radicals substituted by nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Inorganic Chemistry (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20040096390 | 2004-11-23 | ||
PCT/KR2005/003934 WO2006057501A1 (en) | 2004-11-23 | 2005-11-22 | N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1094530A1 true HK1094530A1 (en) | 2007-04-04 |
Family
ID=36498212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK07101468.4A HK1094530A1 (en) | 2004-11-23 | 2007-02-08 | N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt |
Country Status (19)
Country | Link |
---|---|
US (2) | US20090176846A1 (xx) |
EP (2) | EP1701722B1 (xx) |
JP (2) | JP4774053B2 (xx) |
KR (2) | KR100716389B1 (xx) |
CN (3) | CN1905871B (xx) |
AT (1) | ATE445397T1 (xx) |
AU (2) | AU2005307994B2 (xx) |
BR (2) | BRPI0514386B8 (xx) |
CA (2) | CA2552766C (xx) |
DE (1) | DE602005017118D1 (xx) |
DK (1) | DK1701722T3 (xx) |
ES (1) | ES2333739T3 (xx) |
HK (1) | HK1094530A1 (xx) |
IL (2) | IL180985A (xx) |
NZ (1) | NZ555725A (xx) |
PT (1) | PT1701722E (xx) |
RU (1) | RU2361867C2 (xx) |
WO (2) | WO2006057507A1 (xx) |
ZA (2) | ZA200700485B (xx) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2572898C (en) * | 2004-07-05 | 2010-04-20 | Dong Wha Pharmaceutical Ind. Co., Ltd. | Composition for the prevention and treatment of allergic inflammatory disease |
KR20060017929A (ko) * | 2004-08-04 | 2006-02-28 | 동화약품공업주식회사 | 티아졸 유도체가 치환된 신규한 벤즈아미딘 유도체, 그의제조방법 및 이를 유효성분으로 하는 약학 조성물 |
DK1701722T3 (da) * | 2004-11-23 | 2010-01-11 | Dong Wha Pharm Co Ltd | N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt |
MX2009010339A (es) * | 2007-04-19 | 2009-10-16 | Dong Wha Pharm Co Ltd | Sal del acido 2-etanosulfonico de n-hidroxi-4{5-[4-(5-isopropil-2- metil-1,3-tiazol-4-il)fenoxi]pentoxi} benzamidina, procedimiento para su preparacion, y composicion farmaceutica que comprende la misma. |
JP5656258B2 (ja) * | 2011-03-09 | 2015-01-21 | 塩野義製薬株式会社 | ガランタミンを含有する口腔内崩壊錠剤 |
EP2714937B1 (en) | 2011-06-03 | 2018-11-14 | Eisai R&D Management Co., Ltd. | Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds |
HUE042611T2 (hu) † | 2011-07-28 | 2019-07-29 | Rigel Pharmaceuticals Inc | Új (trimetoxifenilamino)pirimidinil készítmények |
JP6292744B2 (ja) * | 2012-09-19 | 2018-03-14 | 富士カプセル株式会社 | 医薬品組成物 |
JP6379044B2 (ja) * | 2013-01-31 | 2018-08-22 | 沢井製薬株式会社 | テルミサルタンとヒドロクロロチアジドとを含有する多層錠剤 |
ES2926687T3 (es) | 2014-08-28 | 2022-10-27 | Eisai R&D Man Co Ltd | Derivado de quinolina muy puro y método para su producción |
US20180028662A1 (en) | 2015-02-25 | 2018-02-01 | Eisai R&D Management Co., Ltd. | Method for Suppressing Bitterness of Quinoline Derivative |
CA2978226A1 (en) | 2015-03-04 | 2016-09-09 | Merck Sharpe & Dohme Corp. | Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer |
CN107530342A (zh) | 2015-04-28 | 2018-01-02 | 安斯泰来制药有限公司 | 口服给药用医药组合物 |
CA2988707C (en) | 2015-06-16 | 2023-10-10 | Eisai R&D Management Co., Ltd. | Combination of cbp/catenin inhibitor and immune checkpoint inhibitor for treating cancer |
US12083227B2 (en) | 2017-08-18 | 2024-09-10 | Abbvie Inc. | Solid pharmaceutical formulations for treating endometriosis, uterine fibroids, polycystic ovary syndrome or adenomyosis |
EA202090461A1 (ru) | 2017-08-18 | 2020-06-29 | Эббви Инк. | Фармацевтические препараты для лечения эндометриоза, миомы матки, синдрома поликистоза яичников или аденомиоза |
KR102276547B1 (ko) * | 2020-09-04 | 2021-07-13 | 주식회사유한양행 | 오메프라졸, 에스오메프라졸 또는 이의 약제학적으로 허용가능한 염을 포함하는 정제 형태의 약학 조성물 및 이의 제조방법 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8518301D0 (en) * | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
EP0379579A4 (en) * | 1988-02-03 | 1991-01-02 | Yoshitomi Pharmaceutical Industries, Ltd. | Pharmaceutical composition having improved releasability |
US5914329A (en) * | 1996-11-26 | 1999-06-22 | Pfizer Inc. | Dimesylate salts of neuropeptide Y ligands |
UA74141C2 (uk) * | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтична композиція на основі тонкоподрібненого еплеренону (варіанти), спосіб її одержання та спосіб лікування розладів, опосередкованих альдостероном (варіанти) |
RU2222529C2 (ru) * | 1999-10-28 | 2004-01-27 | Санкио Компани, Лимитед | Производные бензамидина |
KR100454767B1 (ko) * | 2001-07-19 | 2004-11-03 | 동화약품공업주식회사 | 4-[(4-티아졸릴)페녹시]알콕시-벤즈아미딘 유도체의골다공증 예방 및 치료제로서의 용도 |
KR100789567B1 (ko) * | 2001-11-06 | 2007-12-28 | 동화약품공업주식회사 | 3-아미도-1,2-벤조이소옥사졸 유도체, 그 염, 제조방법 및 용도 |
AU2003219999A1 (en) * | 2002-03-06 | 2003-09-22 | Lifizz, Inc. | Effervescent compositions comprising bisphosphonates and methods related thereto |
BR0309188A (pt) * | 2002-04-12 | 2005-02-09 | Pfizer | Compostos pirazolo como agentes antiinflamatórios e analgésicos |
WO2003101431A1 (en) * | 2002-06-04 | 2003-12-11 | J.B. Chemicals & Pharmaceuticals Ltd. | Pharmaceutical composition for controlled drug delivery system |
CN100342860C (zh) * | 2003-03-18 | 2007-10-17 | 兴和株式会社 | 抗酸剂组合物 |
DK1701722T3 (da) * | 2004-11-23 | 2010-01-11 | Dong Wha Pharm Co Ltd | N-Hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4-yl)phenoxy]pentoxy} benzamidin-2-methansulfonsyresalt |
-
2005
- 2005-11-22 DK DK05817697T patent/DK1701722T3/da active
- 2005-11-22 US US10/584,984 patent/US20090176846A1/en not_active Abandoned
- 2005-11-22 BR BRPI0514386A patent/BRPI0514386B8/pt active IP Right Grant
- 2005-11-22 CA CA2552766A patent/CA2552766C/en active Active
- 2005-11-22 US US11/577,469 patent/US20070254930A1/en not_active Abandoned
- 2005-11-22 KR KR1020050111543A patent/KR100716389B1/ko active IP Right Review Request
- 2005-11-22 AU AU2005307994A patent/AU2005307994B2/en not_active Ceased
- 2005-11-22 WO PCT/KR2005/003950 patent/WO2006057507A1/en active Application Filing
- 2005-11-22 EP EP05817697A patent/EP1701722B1/en active Active
- 2005-11-22 JP JP2007523495A patent/JP4774053B2/ja active Active
- 2005-11-22 EP EP05821036A patent/EP1814593A4/en not_active Withdrawn
- 2005-11-22 NZ NZ555725A patent/NZ555725A/en unknown
- 2005-11-22 WO PCT/KR2005/003934 patent/WO2006057501A1/en active Application Filing
- 2005-11-22 ES ES05817697T patent/ES2333739T3/es active Active
- 2005-11-22 CA CA2585003A patent/CA2585003C/en not_active Expired - Fee Related
- 2005-11-22 DE DE602005017118T patent/DE602005017118D1/de active Active
- 2005-11-22 RU RU2007123614/04A patent/RU2361867C2/ru active
- 2005-11-22 CN CN2005800017444A patent/CN1905871B/zh active Active
- 2005-11-22 AU AU2005300239A patent/AU2005300239B2/en active Active
- 2005-11-22 JP JP2007542909A patent/JP4773456B2/ja not_active Expired - Fee Related
- 2005-11-22 BR BRPI0517396-5A patent/BRPI0517396A/pt not_active IP Right Cessation
- 2005-11-22 KR KR1020050111779A patent/KR101047042B1/ko not_active IP Right Cessation
- 2005-11-22 PT PT05817697T patent/PT1701722E/pt unknown
- 2005-11-22 CN CN200580038889A patent/CN100574756C/zh not_active Expired - Fee Related
- 2005-11-22 AT AT05817697T patent/ATE445397T1/de active
- 2005-11-22 CN CN2009101666678A patent/CN101693029B/zh not_active Expired - Fee Related
-
2007
- 2007-01-17 ZA ZA200700485A patent/ZA200700485B/en unknown
- 2007-01-25 IL IL180985A patent/IL180985A/en active IP Right Grant
- 2007-02-08 HK HK07101468.4A patent/HK1094530A1/xx unknown
- 2007-04-18 IL IL182647A patent/IL182647A/en not_active IP Right Cessation
- 2007-05-24 ZA ZA200704236A patent/ZA200704236B/xx unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1094530A1 (en) | N-hydroxy-4-{5-[4-(5-isopropyl-2-methyl-1,3-thiazol-4- yl)phenoxy]pentoxy}benzamidine 2 methansulfonic acid salt | |
WO2003097622A3 (en) | Synthesis of 2-alkylcysteines, 2-(hydroxylated phenyl)-4-alkylthiazoline-4-carboxylic acids and derivatives thereof | |
WO2009025983A3 (en) | Method for preparing 5-haloalkyl-4,5-dihydroisoxazole derivatives | |
CY1107238T1 (el) | Παρασκευη μιας πολυμορφικης μορφης ενος παραγωγου θειαζολιδινοδιονης | |
TW200637822A (en) | Process for the preparation of a 2-pyridylethylcarboxamide derivative | |
TW200633981A (en) | Process for the preparation of a 2-ethylaminopyridine derivative | |
UA92354C2 (xx) | Амінокислі солі росиглітазону$аминокислые соли росиглитазона | |
WO2008126899A1 (ja) | 5員環へテロ環誘導体及びその医薬用途 | |
WO2006003471A3 (en) | Process for the preparation of pramipexole by chiral chromatography | |
WO2005105749A3 (en) | Process for making montelukast and intermediates therefor | |
EP1541570A4 (en) | NEW PHYSIOLOGICALLY ACTIVE SUBSTANCE | |
CA2665931C (en) | Hydrobenzamide derivatives as inhibitors of hsp90 | |
WO2011141933A3 (en) | Process for preparation of 2-[3-cyano-4-(2-methylpropoxy)phenyl]-4-methylthiazole-5-carboxylic acid and its pharmaceutically acceptable salts | |
WO2007057225A3 (en) | Process for making montelukast and intermediates therefor | |
WO2008133128A1 (ja) | 縮合複素環誘導体、それを含有する医薬組成物及びその医薬用途 | |
BRPI0607085A2 (pt) | derivados de oximas heterocìclicos, o respectivo processo de preparação e a respectiva utilização como agentes hipoglicemiantes e hipolipemiantes | |
GB0410013D0 (en) | Process | |
WO2009012201A3 (en) | Process for the preparation of trifluoroalkyl-phenyl and heterocyclic sulfonamides | |
WO2005012273A3 (en) | Process for the preparation of substituted thiazoles | |
EP2146974A4 (en) | SALT OF N-HYDROXY-4- {5- [4- (5-ISOPROPYL-2-METHYL-1,3-THIAZOL-4-YL) PHENOXY] PENTOXY} BENZAMIDINE 2-ETHANESULPHONIC ACID, ITS PREPARATION METHOD AND COMPOSITION PHARMACEUTICAL COMPRISING IT | |
WO2009069311A1 (ja) | 3-メルカプトアニリン化合物の製造法 | |
WO2005021542A3 (en) | Process for the preparation of pioglitazone | |
WO2006021654A8 (fr) | Derives de 4-arylmorpholin-3-one, leur preparation et leur application en therapeutique | |
WO2008010089A3 (en) | Process for preparation of intermediates of rosiglitazone, rosiglitazone and polymorphic forms thereof | |
AU2003269479A1 (en) | Phosphoric acid salt of 5-((4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) methyl)-2, 4-thiazolidinedione |